Details of the Drug Combination

General Information of Drug Combination (ID: DCASY1N)

Drug Combination Name

Vinflunine Hepzato

Indication

Disease Entry	Status	REF
Adult acute myeloid leukemia	Investigative	[1]

Component Drugs

Vinflunine DMTJAEP

Hepzato DM2AZPP

Small molecular drug

N.A.

High-throughput Screening Result

Testing Cell Line: HL-60(TB)

Zero Interaction Potency (ZIP) Score: 1.2

Bliss Independence Score: 4.15

Loewe Additivity Score: 0.65

LHighest Single Agent (HSA) Score: 0.31

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Carcinoma	DCFLQAD	MCF7	Investigative	[4]
Adenocarcinoma	DCLOPGX	HT29	Investigative	[5]
Adenocarcinoma	DCBFZHO	HCT-15	Investigative	[5]
High grade ovarian serous adenocarcinoma	DC9X6C6	OVCAR-5	Investigative	[5]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
4	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.